Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up surveyCOVID-19 대유행 2년차에 대한 아시아 태평양 전망: 후속 조사Article Published on 2022-08-012022-09-12 Journal: Clinical and experimental allergy : journal of the [Category] Coronavirus, 진단, [키워드] Adverse reaction anaphylaxis Anti-viral anticipated Asia Baricitinib Care changes in cilgavimab clinical complement contributed Coronavirus disease 2019 country COVID-19 COVID-19 disease COVID-19 vaccination programme Dexamethasone Endemic endemic diseases Epidemiology Follow-up force incidence males mild-to-moderate disease morbidity and mortality mRNA neutralizing antibody novel Pacific Association pandemic Perspective preventive measures Prophylaxis public health public health measure question Remdesivir response Ritonavir severe disease Severe infection survey Therapeutics Tixagevimab vaccination Vaccine [DOI] 10.1111/cea.14191 PMC 바로가기 [Article Type] Article
Emerging Therapies for COVID-19: The Value of Information From More Clinical TrialsCOVID-19에 대한 새로운 치료법: 더 많은 임상 시험에서 얻은 정보의 가치Article Published on 2022-08-012022-09-11 Journal: Value in health : the journal of the International [Category] 임상, 진단, [키워드] Analysis approval approved Baricitinib benefit Casirivimab clinical clinician Cohort consequence Cost-benefit analysis COVID-19 COVID-19 pandemic decision support techniques Dexamethasone drug approval. effective Emergency use authorization Evidence Health healthcare hospitalized patient hospitalized patients Hydroxychloroquine Imdevimab implementation information interferon interferon beta Interferon beta-1a Lopinavir Lopinavir-ritonavir outcome pandemic Perspective Randomized controlled trial RCT RCTs Remdesivir Research Ritonavir seeking Support therapy threshold Tocilizumab usual care value with COVID-19 [DOI] 10.1016/j.jval.2022.03.016 PMC 바로가기 [Article Type] Article
The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19COVID-19가 있는 중환자에서 덱사메타손과 토실리주맙을 사용하는 CRP의 유용성Article Published on 2022-08-012022-09-12 Journal: Journal of critical care [Category] 바이오마커, 진단, [키워드] Critically ill patient CRP Dexamethasone utility with COVID-19 [DOI] 10.1016/j.jcrc.2022.154053 PMC 바로가기 [Article Type] Article
Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic ReviewReview article Published on 2022-08-012022-10-05 Journal: Endocrine practice : official journal of the American College of [Category] 임상, 진단, [키워드] added article clinical guideline Cochrane Library conducted Controlled trial COVID-19 COVID-19 pandemic database Dexamethasone diabetes effective End points evaluated glucocorticoid hyperglycemia Including insulin management objective Patient patients with COVID-19 RCT RCTs regimens Respiratory Support Result review Standard of care steroid Support synonym systematic review treatment strategy variety Web of Science widespread [DOI] 10.1016/j.eprac.2022.07.014 [Article Type] Review article
SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1SARS-CoV-2 감염은 IRF1을 통해 폐, 간, 지방 조직 및 췌장 세포의 인슐린/IGF 신호 전달 경로를 손상시킵니다Article Published on 2022-08-012022-09-11 Journal: Metabolism: clinical and experimental [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] Activation adeno-associated virus adipose Adipose tissue AKT ameliorated analyzed association Autopsy Calu3 Calu3 cell CaLu3 cells Cell cell survival cells condition contribute COVID-19 COVID-19 pathology COVID-19 patient COVID-19 patients COVID-19 severity Critical critical patient critical patients cytokine determine Dexamethasone diabetes Diabetic diabetic patients Dihydrotestosterone Endocrine energy metabolism European population evaluate Evidence exacerbated exhibited Gain Gene Expression Genes GFP HEK293T Hospitalized Host human ACE2 human cells hyperglycemia impair impairment infected with SARS-CoV-2 insulin insulin resistance Insulin signaling Insulin/IGF signaling pathway interferon regulatory factor Interferone intron IRF1 liver lung Lungs male Male sex MAPK metabolic metabolic abnormalities Metabolic abnormality metabolism mouse model mTOR Multiorgan dysfunction Multiple organ damage Non-COVID-19 Non-COVID-19 patients obese obesity Older Older age Organoid overexpressing pancreatic Pancreatic cell pancreatic islets pathology patients patients with COVID-19 PI3K potential mechanism Prevalence provide Regulation reported Repository risk factor Risk factors SARS-CoV-2 SARS-CoV-2 infected cell SARS-CoV-2 infected cells SARS-COV-2 infection serotype severe COVID-19 severity Signaling signaling pathway significantly stem cell survival tissue tissue damage Tissue damage. tissues Transcriptome transcriptome dataset transcriptome datasets Transgenic mouse variant Whole blood whole blood transcriptome with COVID-19 [DOI] 10.1016/j.metabol.2022.155236 PMC 바로가기 [Article Type] Article
Addition of Baricitinib to COVID-19 Treatment Does Not Increase Bacterial Infection Compared to Standard Therapy: A Single-center Retrospective StudyArticle Published on 2022-08-012023-07-09 Journal: Internal medicine (Tokyo, Japan) [Category] COVID19(2023년), [키워드] Baricitinib COVID-19 Dexamethasone Remdesivir [DOI] 10.2169/internalmedicine.9534-22 PMC 바로가기
Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling이중 작용 항바이러스/항염 소분자 및 생리학적 기반 약동학 모델링을 통한 COVID-19에 대한 새로운 치료법 개발Review Published on 2022-07-202022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] (dexamethasone Anti-inflammatory Anti-SARS-CoV-2 Activity Antiviral antiviral agent Antiviral agents approach Baricitinib biochemical pathway Biochemical pathways characterization COVID-19 COVID-19 pandemic Critical Cytopathic effect develop Developing Dexamethasone drug target dual dual action early treatment effective Efficacy and safety health system health systems High-risk patients identify in silico in vitro in vivo model Infection inflammatory cascade inhibitor inhibitors mechanism Mild mild to moderate Mild to moderate COVID-19 modeling Moderate COVID-19 molecular docking molecule molnupiravir monoclonal antibodies multidisciplinary approach New Nirmatrelvir pandemic pathogen PBPK modeling pharmacological protocol Ritonavir therapeutic agent therapeutic agents threat Treatment treatment of COVID-19 Viral virus viruses [DOI] 10.3390/ijms23148006 PMC 바로가기 [Article Type] Review
Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort대규모 용도 변경 노력에서 VERO-E6 세포에 대한 세포변성 SARS-CoV-2 스크리닝Article Published on 2022-07-132022-09-11 Journal: Scientific Data [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] accelerate anti-inflammatory drug approach Cell Compound COVID-19 COVID-19 disease Dexamethasone Drug discovery drugs effective effort greater highlighting idea identify inhibitor Intensive mechanism Patient patients phenotypic phenotypic screening potential therapies potential therapy reducing mortality Remdesivir repertoire Repurposed drug Repurposed drugs SARS-CoV-2 SARS-COV-2 infection screened shown Support Time to recovery viral infection [DOI] 10.1038/s41597-022-01532-x PMC 바로가기 [Article Type] Article
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical TrialClinical Trial Published on 2022-07-042022-10-04 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome adverse effect ARDS bone Bone marrow cells cellular cellular therapy clinical Cohort control patient control patients COVID-19 COVID-19 disease Critical D-dimer value Dexamethasone Efficacy Endocarditis evaluate extracorporeal membrane oxygenation group high mortality High-flow nasal oxygen Immune cell Immune-mediated induce Inflammation Inflammatory response intensive care intensive care unit (ICU) interval intravenous infusion invasive Invasive mechanical ventilation limit mechanical ventilation median Mesenchymal stromal cells MSC MSC-treated MSCs nasal no significant difference observation outcome oxygen Patient patients phase phenotype Randomized controlled trial Regulatory reported required requiring supplemental oxygen Result Safe SARS-CoV-2 severe COVID-19 significantly higher significantly lower Statistical tests stimulate stroke stromal cell survival syndrome therapy tissue repair treated Trial [DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trialResearch article Published on 2022-07-012022-10-05 Journal: Advances in biological regulation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] Baricitinib benefit benefits of treatment common diseases COVID-19 COVID-19 therapy Dexamethasone drug enrolled Establishing evaluate experience hospitalised identify moderate numbers of patient pandemic Patient Randomised Evaluation recovery RECOVERY trial recruitment routine clinical care shown the SARS-CoV-2 Tocilizumab Treatment Trial with COVID-19 [DOI] 10.1016/j.jbior.2022.100901 [Article Type] Research article